Membranous Nephropathy Clinical Trial
Official title:
Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis
To assess the correlation of these urinary biomarkers with the serum sample and evaluated the clinical utility of using urinary sample in the detection and prognostication of MGN. Fifty patients with newly diagnosed biopsy proven MGN would be recruited and followed up for 1 years. Serum and urinary biomarkers would be collected every 4 months and their antibody titres measured with ELISA assay.
The uses of phospholipase A2 receptor and thrombospondin domain containing 7A antibodies have transformed the management of membranous glomerulonephritis (MGN). However, these are mostly based on serum and the utility of urinary biomarkers are yet to be established. The aim of this study is to assess the correlation of these urinary biomarkers with the serum sample and evaluated the clinical utility of using urinary sample in the detection and prognostication of MGN. Fifty patients with newly diagnosed biopsy proven MGN would be recruited and followed up for 1 years. Serum and urinary biomarkers would be collected every 4 months and their antibody titres measured with ELISA assay. The primary outcome would be the correlation of the urinary biomarkers with the corresponding serum markers. The secondary outcome would be the correlation of the urinary biomarkers with clinical parameters such as the slope of eGFR decline, composite renal events such as time to need for renal replacement therapy or renal death and response to treatments. By establishing the clinical correlation of these urinary biomarkers, the use of such biomarkers would be a more attractive option given its non-invasive nature and conveniences as compared to serum samples. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04095156 -
Autoreactive B Cells in Membranous Nephropathy
|
||
| Not yet recruiting |
NCT06341205 -
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
|
Phase 3 | |
| Active, not recruiting |
NCT04893096 -
MOR202 for Refractory MN
|
Phase 2 | |
| Completed |
NCT00405340 -
Rituximab in the Treatment of Idiopathic Membranous Nephropathy
|
Phase 0 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Active, not recruiting |
NCT04652570 -
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06242327 -
An Outcome Analysis of Primary Membranous Nephropathy
|
||
| Recruiting |
NCT03929887 -
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
|
||
| Active, not recruiting |
NCT03949855 -
Belimumab With Rituximab for Primary Membranous Nephropathy
|
Phase 2 | |
| Completed |
NCT00983034 -
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
|
N/A | |
| Completed |
NCT03025828 -
Adrenocorticotropic Hormone in Membranous Nephropathy
|
Phase 4 | |
| Recruiting |
NCT05732402 -
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT04571658 -
NEPTUNE Match Study
|
||
| Active, not recruiting |
NCT05894512 -
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
|
||
| Not yet recruiting |
NCT05941845 -
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
|
Phase 2 | |
| Completed |
NCT00518219 -
To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
|
Phase 4 | |
| Completed |
NCT02199145 -
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
|
N/A | |
| Not yet recruiting |
NCT04326218 -
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
|
N/A | |
| Active, not recruiting |
NCT03453619 -
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
|
Phase 2 | |
| Completed |
NCT01955187 -
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy
|
Phase 3 |